Current News

Eden Research plc (AIM: EDEN), the agrochemical and encapsulation development company, announces that it has appointed Walbrook PR Ltd as its Financial PR advisor. Walbrook will advise Eden Research on its communications with the financial media, research analysts and other small cap investor groups in London and the regions, following its admission to AIM on Friday 11 May 2012.

Eden Research withdrew from trading on PLUS on Thursday 10 May 2012 and shares were admitted to trade on AIM on Friday 11 May 2012, trading under the trading symbol EDEN.

Eden Research is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants and also can be used with hydrophobic compounds both natural and synthetic. Work to date has focussed on the antimicrobial properties of terpenes which are naturally occurring low-toxicity botanical substances, produced by most plants as part of their defence mechanisms. The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry.

Paul McManus, Director of Walbrook PR, said: "We are very pleased to work with the Eden team on their move from PLUS to AIM and we look forward to increasing Eden's profile within the UK capital markets as it works with partners across a variety of industries to licence their technology for commercial use."